Laboratory Bulletin

Date: **June 14, 2010**

To: **Alberta Health Services**
Physicians, Cross Cancer Institute (CCI) – Administration, Oncologists, Out Patient Department, Nursing Units, Pharmacy, Diagnostic Imaging, Radiation Therapy, Clinical Research Unit, Tom Baker Cancer Centre (TBCC) Translational Laboratory, Laboratory Directors and Managers

From: **Laboratory Services, Cross Cancer Institute (CCI) and *DynaLIFE$_{DX}$***

Re: **Transition of Powerpath to CoPath Laboratory Information Systems (LIS)**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

The Cross Cancer Institute Laboratory Information System supporting **Pathology** will transition from Powerpath to CoPath on **Monday, June 21, 2010.**

Why this is important:

This transition will provide consistency with laboratory result reporting across the Edmonton Zone. Following the transition, Anatomic Pathology test results for Cancer Care patients will be accessible in both Netcare and the CCI Aria Hospital Information system. Paper distribution of laboratory reports will continue using the attached report format example.

Your cooperation and patience as we continue to improve our laboratory infrastructure are appreciated.

Inquiries and feedback may be directed to:

Betty Allen, Manager, Cancer Services at (780) 432-8705

This bulletin has been reviewed and approved by Dr.Fiona Bamforth and Dr. Tom Higa.

CROSS CANCER INSTITUTE
Department of Laboratory Medicine
11560 University Avenue
Edmonton, Alberta T6J 1Z2
Phone: 780-432-8454 Fax: 780-432-8455

Patient Name:	**TESTPATIENT, LAB**			Loc/Rm #:	UNKO
PHN. #:	014078145182			Phys:	LIS, TEST DOCTOR
DOB:	10/23/1991 (Age: 18)	Sex:	F		LIS
Chart #:	U10-234 - block 3R				
Pt. Home Phone #:	(780)999-9999				
Health Record No.:	014078145182				
Prov./ Postal Code:	AB				

CCI - Biomarker Report

Accession #:	**HR10-604**	**Specimen Type**: Right breast	
Collected:	6/8/2010		
Received:	6/8/2010		
Reported:	6/9/2010		

Original Report

Specimen History:
Slides ordered from UAH U10-234 - block 3R.

BIOMARKER IMMUNOHISTOCHEMISTRY RESULTS:

ESTROGEN RECEPTOR (SP1): **ER POSITIVE (1+ STRONG)**

PROGESTERONE RECEPTOR (PgR636): **PR POSITIVE (1+ STRONG)**

QA retest for ER and PR only: Discordant results attributed to possible pre-analytical, fixation differences

HER-2/neu PROTEIN (polyclonal): **HER-2 NOT PERFORMED**

IHC Comment: Her-2 done previously in H10-123.

Electronically Signed Out (6/9/2010 12:00:44)

jj/6/9/2010

Analytical Test Information:
Implementation Date: 20 May 2010

ER clone SP1 rabbit monoclonal; slide incubated with the pre-dilute SP1 monoclonal antibody from Ventana Medical Systems, Tucson, AZ for 16 minutes and visualized with DAB chromogen.
PR clone 636 mouse monoclonal; slide incubated with the PgR636 monoclonal antibody from DakoCytomation, Carpinteria, CA at a 1:40 dilution for 30 minutes and visualized with DAB chromogen.
ER and PR immunoreactivity localization: nuclear. Unless otherwise stated, all results refer to invasive neoplasm.
Her-2 (cerb-b2 oncoprotein polyclonal; slide incubated with the A0485 polyclonal antibody from DakoCytomation, Carpinteria, CA at a 1:100 dilution for 30 minutes and visualized with DAB chromogen.
HER-2 immunoreactivity localization: circumferential membrane.
ER and PR proportion positive score: 0 (zero or <1%), 1 (1% to 10%), 2 (>10% to 67%), 3 (>67%).
HER-2 result category 0 or 1+: Zero staining or weak 1+ incomplete membrane staining in any percentage of cells.
HER-2 result category 2+: Strong complete membrane staining (chicken wire pattern) in up to 30% of cells and weak/moderate heterogeneous complete membrane staining in at least 10% of cells.

- END OF REPORT -